CellCura ASA (Oslo Axess: CELL), announces its results for the first quarter, 2014. A presentation will be held at 9 PM today at the Company's office at Vika Atrium, Munkedamsveien 45 A, 5th floor, Oslo.


Higlights from the quarter and subsequent period:
· CellCura has been working on a revised version of the ERM workstation (version 1.5) which will feature reduced production costs and new features. The new features can be retrofitted to the current installation base as part of a future upgrade package.


· CellCura has been focusing on expanding the existing customers' solutions with new modules in order to cover more of the processes in the clinics.
· CellCura has fine-tuned the composition of certain PFM products on the back of advice from the original inventor. This has been completed in order to further enhance specific value adding properties of certain media types. A new batch has been produced and tested, with products shipped to complete the first orders.


· The company is working on growing sales in unregulated markets and have already signed and expect to sign new distributor agreements in SE Asia. This will allow the company to further develop its sales and distribution platform ahead of introducing products to regulated markets once the CE approval is in place.

Quarterly report attached.

Oslo, 30 May 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

distributed by